NAC
- Katie Dollar, Pharm D
- Sep 20, 2024
- 1 min read
Citations:
Tirouvanziam R, et al. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4628-33.
Tse HN, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013 Jul;144(1):106-118.
Sutherland ER, et al. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006 Dec;3(4):195-202.
De Flora S, et al. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997 Jul;10(7):1535-41.
Teskey G, et al. The Synergistic Effects of the Glutathione Precursor, NAC and First-Line Antibiotics in the Granulomatous Response Against Mycobacterium tuberculosis. Front Immunol. 2018 Sep 12;9:2069.
Comments